Suleiman Massarweh
Title
Cited by
Cited by
Year
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer
J Shou, S Massarweh, CK Osborne, AE Wakeling, S Ali, H Weiss, R Schiff
Journal of the National Cancer Institute 96 (12), 926-935, 2004
13352004
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
CK Osborne, J Shou, S Massarweh, R Schiff
Clinical cancer research 11 (2), 865s-870s, 2005
5042005
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
S Massarweh, CK Osborne, CJ Creighton, L Qin, A Tsimelzon, S Huang, ...
Cancer research 68 (3), 826-833, 2008
4972008
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
R Schiff, SA Massarweh, J Shou, L Bharwani, SK Mohsin, CK Osborne
Clinical Cancer Research 10 (1), 331s-336s, 2004
4752004
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response
R Schiff, S Massarweh, J Shou, CK Osborne
Clinical Cancer Research 9 (1), 447s-454s, 2003
4152003
Treatment of human epidermal growth factor receptor 2–overexpressing breast cancer xenografts with multiagent HER-targeted therapy
G Arpino, C Gutierrez, H Weiss, M Rimawi, S Massarweh, L Bharwani, ...
Journal of the National Cancer Institute 99 (9), 694-705, 2007
2002007
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk
S Massarweh, R Schiff
Endocrine-related cancer 13 (Supplement_1), S15-S24, 2006
1942006
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor–positive, HER-2/neu-positive breast cancer
S Massarweh, CK Osborne, S Jiang, AE Wakeling, M Rimawi, SK Mohsin, ...
Cancer research 66 (16), 8266-8273, 2006
1782006
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
R Schiff, SA Massarweh, J Shou, L Bharwani, G Arpino, M Rimawi, ...
Cancer chemotherapy and pharmacology 56 (1), 10-20, 2005
1762005
Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities
S Massarweh, R Schiff
Clinical Cancer Research 13 (7), 1950-1954, 2007
1532007
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
CJ Creighton, S Massarweh, S Huang, A Tsimelzon, SG Hilsenbeck, ...
Cancer research 68 (18), 7493-7501, 2008
1432008
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts
MF Rimawi, LS Wiechmann, YC Wang, C Huang, I Migliaccio, MF Wu, ...
Clinical Cancer Research 17 (6), 1351-1361, 2011
792011
Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
S Massarweh, E Romond, EP Black, E Van Meter, B Shelton, ...
Breast cancer research and treatment 149 (2), 565-565, 2015
67*2015
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
S Massarweh, E Romond, EP Black, E Van Meter, B Shelton, ...
Breast cancer research and treatment 143 (2), 325-332, 2014
662014
Textbook of uncommon cancer
D Raghavan, MS Ahluwalia, CD Blanke, J Brown, ES Kim, GH Reaman, ...
John Wiley & Sons, 2017
612017
Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan
MA Sughayer, MM Al-Khawaja, S Massarweh, M Al-Masri
Pathology & Oncology Research 12 (2), 83-86, 2006
552006
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens
MM Morrison, K Hutchinson, MM Williams, JC Stanford, JM Balko, ...
The Journal of clinical investigation 123 (10), 4329-4343, 2013
522013
Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2 …
S Massarweh, J Shou, SK Mohsin, M Ge, AE Wakeling, CK Osborne, ...
Proc Am Soc Clin Oncol 21, 33a, 2002
452002
Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and …
A Alqaisi, L Chen, E Romond, M Chambers, M Stevens, G Pasley, ...
Breast cancer research and treatment 148 (2), 437-444, 2014
372014
Case 3. Solitary splenic metastasis in lung cancer with spontaneous rupture
S Massarweh, H Dhingra
Journal of clinical oncology 19 (5), 1574-1575, 2001
372001
The system can't perform the operation now. Try again later.
Articles 1–20